4-氨基-5-氯-2-乙氧基-N-(吗啉-2-基甲基)苯甲酰胺 | 152013-26-8

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-5-氯-2-乙氧基-N-(吗啉-2-基甲基)苯甲酰胺
• 中文别名: 莫沙必利杂质J
• 英文名称: 4-amino-5-chloro-2-ethoxy-N-(morpholin-2-ylmethyl)benzamide
• CAS: 152013-26-8
• 化学式: C₁₄H₂₀ClN₃O₃
• 分子量: 313.78
• InChiKey: HQOQHUQAQLNFOP-UHFFFAOYSA-N

物化性质

• 熔点：
  137-140°C
• 沸点：
  477.8±45.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（轻微）、甲醇（非常轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  85.6
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：Kato Shiro

  公开号：US20100249399A1

  公开（公告）日：2010-09-30

  Disclosed is a compound having a strong affinity to serotonin-4 receptors, which is useful as an enterokinesis-promoting agent or a digestive tract function-improving agent. Specifically, disclosed is a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. Also specifically disclosed is a pharmaceutical composition containing a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. [In Formula (1), Ar represents a group represented by Formula (Ar-1) or Formula (Ar-2).]

  揭示了一种具有强烈亲和力的化合物，对5-羟色胺-4受体具有亲和力，可用作促进肠动力或改善消化道功能的药剂。具体地，揭示了一种由化学式（1）表示的化合物或其药学上可接受的盐。还具体揭示了一种含有由化学式（1）表示的化合物或其药学上可接受的盐的药物组合物。【在化学式（1）中，Ar代表由化学式（Ar-1）或化学式（Ar-2）表示的基团。】
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Substituted morpholinyl compounds
  申请人：Persichetti Rose A.

  公开号：US20080261983A1

  公开（公告）日：2008-10-23

  This disclosure relates to novel substituted morpholinyl compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a 5HT4 serotonin receptor agonist.

  本公开涉及新颖的取代吗啉基化合物及其衍生物，其药用可接受的盐、溶剂化合物和水合物。本公开还提供了包含本公开化合物的组合物，并使用这些组合物在治疗通过给予5HT4 5-羟色胺受体激动剂治疗有益的疾病和症状的方法。
• DEUTERATED MORPHOLINYL COMPOUNDS
  申请人：Concert Pharmaceuticals Inc.

  公开号：EP2148867A1

  公开（公告）日：2010-02-03
• Compositions and methods for treatment of viral diseases
  申请人：Johansen Lisa M.

  公开号：US20080161324A1

  公开（公告）日：2008-07-03

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.